Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC-FFCD 9710

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1351-1361

  Dahan, Laetitia ^a   Bonnetain, Frank ^b   Rougier, Philippe ^c   Raoul, Jean Luc ^d   Gamelin, Eric ^e   Etienne, Pierre Luc ^f   Cadiot, Guillaume ^g   Mitry, Emmanuel ^d   Smith, Denis ^h   Cvitkovic, Frédérique ⁱ   Coudert, Bruno ^j   Ricard, Floriane ^a   Bedenne, Laurent ^a   Seitz, Jean François ^a  

^a TIMONE HOSPITAL   (France)

^b FFCD   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

^e CENTRE PAUL PAPIN   (France)

^f Clinique Armoricaine de Radiologie   (France)

^g SERVICE DE DERMATOLOGIE   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ CENTRE RENÉ HUGUENIN   (France)

^j Georges Francois Leclerc Center   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; FLUOROURACIL; PARACETAMOL; RECOMBINANT ALPHA2A INTERFERON; STREPTOZOCIN;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOID; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININEMIA; CREATINNINEMIA; DIARRHEA; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN DEFICIENCY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; DISEASE PROGRESSION; ENDOCRINE GLAND NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; INTERFERON ALFA-2A; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; STREPTOZOCIN; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 72549103551     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0104     Document Type: Article

References (24)

1. Arnold R, Rinke A, Klose KJ, Müller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P & Moll R 2005 Octreotide versus octreotide plus interferon-α in endocrine gastropancreatic tumors: a randomized trial. Clinical Gastroenterology and Hepatology 3 761-771. (Pubitemid 41116728)
2. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, Wied M, Mayer C, Aminossadati B & PROMID Study Group 2009 Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. Proceedings of the American Society of Clinical Oncology 27 4508.
3. Conseil Scientifique de la FFCD 2003 What can be done for patients with cancer of the digestive tract in 2003? Guidelines of the Francophone Federation of Digestive Tract Cancerology Gastroenterologie Clinique et Biologique 27 43-58.
4. Detjen KM, Welzel M, Farwig K, Brembeck FH, Kaiser A, Riecken EO, Wiedenmann B & Rosewicz S 2000 Molecular mechanism of interferon α-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 118 735-748. (Pubitemid 30171623)
5. Dirix LY, Vermeulen PB, Fierens H, De Schepper B, Corthouts B & Van Oosterom AT 1991 Long-term results of continuous treatment with recombinant interferon-α in patients with metastatic carcinoid tumors - an antiangiogenic effect? Anticancer Drugs 7 175-181.
6. Engstrom PF, Lavin PT, Moertel CG, Folsch E & Douglass HO Jr 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology 2 1255-1259.
7. Eriksson B, Kloppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G et al. 2008 Consensus Guidelines for the management of patients with digestive neuroendocrine tumors - well differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87 8-19. (Pubitemid 350308290)
8. Faiss S, Pape UF, Böhming M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B & International Lanreotide and Interferon Alfa Study Group 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon α and their combination for therapy of metastatic neuroendocrine gastropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689-2696.
9. Gonzalez MA, Biswas S, Clifton L & Corrie PG 2003 Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. British Journal of Cancer 89 455-456. (Pubitemid 37026423)
10. Haller DG, Schutt A, Dayal Y, Ryan L & Lipsitz S 1990 Chemotherapy for metastatic carcinoid tumors: an ECOG phase II-III trial. Proceedings of the American Society of Clinical Oncology 9 102.
11. Kolby L, Persson G, Franzen S & Ahrén B 2003 Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours. British Journal of Surgery 90 687-693. (Pubitemid 36760596)
12. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C & Faivre J 2004 Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53 549-553. (Pubitemid 38372980)
13. Moertel CG & Hanley JA 1979 Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clinical Trials 2 327-334. (Pubitemid 10021790)
14. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC & Meric-Bernstam F 2008 Antitumor activity of rapamycin and octreotide as single agents or in combination neuroendocrine tumors. Endocrine-Related Cancer 15 257-266.
15. Nave H, Mossinger E, Feist H, Lang H & Raab H 2001 Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric, study over 13 years. Surgery 129 170-175. (Pubitemid 32158579)
16. Oberg K 1992 The action of interferon α on human carcinoid tumours. Seminars in Cancer Biology 3 35-41.
17. Oberg K 2000 Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 92-97. (Pubitemid 30665946)
18. Oberg K & Eriksson B 1991 The role of interferons in the management of carcinoid tumours. British Journal of Haematology 79 74-77.
19. Oberg K, Funa K & Alm G 1983 Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. New England Journal of Medicine 309 129-133.
20. Oberg K, Norheim I & Alm G 1989 Treatment of malignant carcinoid tumors: a randomized controlled study of streptozotocin plus 5-FU and human leukocyte interferon. European Journal of Cancer and Clinical Oncology 25 1475-1479. (Pubitemid 19247456)
21. Pavel ME, Baum U, Hahn EG, Schuppan D & Lohmann T 2006 Efficacy and tolerability of pegylated IFN-α in patients with neuroendocrine gastroenteropancreatic carcinomas. Journal of Interferon & Cytokine Research 26 8-13. (Pubitemid 43201732)
22. Stuart K, Levy DE, Anderson T, Axiotis CA, Dutcher JP, Eisenberg A, Erban JK, Benson AB III & Eastern Cooperative Oncology Group 2004 Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Investigational New Drugs 22 75-81.
23. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG & Eastern Cooperative Oncology Group 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23 4897-4904.
24. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL & Ajani JA 2008 Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignement phase II study of depot octreotide with bevacizumab and pegylated interferon α-2b. Journal of Clinical Oncology 26 1316-1323.